XX% the our revenue the fourth call. million, $XX.X Throughout applications throughout continued customers in I for and their Good critical-to-life ended XXXX morning our to quarter customers. team We revenue, we thank you XXXX for XXXX Kelly. serving want for to earnings dedication fourth million our and our Thanks, support to year. our from our year. mission commitment joining with on prior total $XX.X of bringing the the up to thank quarter
grew the in XX%, our than our line growth expectations. with desktop year, our Xx more For rate full by revenue overall at
year-over-year. increase than recurring contributions strong revenue saw also more XXX% We
While macroeconomic underlying as progress need forecasted adverse the remain products our strong impaired QX. factors for our in
to we them protracted purchasing began previously and see capital to in see we mid-XXXX, cycles As communicated, here in QX. continue
persist feel needed anticipate half I'm and success. doing headwinds the through the we trajectory confident we these both XXXX, are our in While near-term and long-term groundwork industry of for long-term to first
We we more our rein have keeping shortly are a on expenses. regard. operating will tight that in recent some Joe actions taken provide on details
analytics We of developing robust new products meet demand are need. to launching at the point and growing the for
a multiple end bioprocessing, research, We retaining years markets, cash position are are runway. pursuing forensics, with of and diversified solid importantly, we and
throughout We some have progress made encouraging the year.
Now customer driving progress I'd a our five update XXXX. the adoption. our first objective brief set like focus provide areas to for we on Starting with across of
XX one devices our XX XXX with pharmaceutical more adding a having Nearly combined ZipChip of dozen now For REBEL to or devices, each base over grew these year. companies than XX are more. half placements quarter the desktops, and we a our devices within top accounts
our conversations our customers to broaden we develop, additional allows This important as larger across bio-analytic top products. it is combined ability us pharma launch serve as define, and these and strengthens to footprint
also by XXXX year-over-year year, We customers' more new looking consumable REBEL intent orders priorities. with REBEL placed second revenues indicating have base QX, devices purchases also future XX%. broadening through our were new consumable customers REBEL than orders the been existing. our of users service from at highest their number seeding opportunity Desktop full more of customers. with to received into two When thirds of we than and In our incorporate scheduled were up roughly
for a more under preclinical are process XXXX, and pressure enthusiasm and still our bioprocessing customers to second development industry more underlying the the we for analytics While fundamental seeing enable half products we have advanced in therapeutics. the need become seen specifically of strong
Our there a to and therapies years. our therapies driver has Regenerative trials the desktop pipeline gene forecasted expanding of for from of increase being of the is mid-year Medicine, clinical of up are cell are Alliance cell coming advanced the XX% X,XXX therapies, now in support key an XXXX, According and the devices been in advanced worldwide. slightly total number today used addressable in active for developers therapy year-over-year and market there
corporate the investments in main Miami and this a analytics. to need Advanced the Week January, Therapies was in At Conference recent theme digitization accelerate
ran the transition for analytics good from messaging at-line connected offline need and instruments clear. to manual and disparate solutions Our automated online
past MXXXX we over our devices the For base our year. handhelds, X,XXX XXX adding devices grew
this the XX,XXX to individuals of of adoption. continues than deaths As the annually. year’s with more tragically, Address, crisis be State mentioned in crisis driver Union customer major of a United opioid This States continues President
In deadly Post in December, The a ran Washington series on weeklong U.S. fentanyl the surge
when seasoned Security investigations MXXXX to street. profiled hits the of determine uses article Homeland a device a first batch lethal seems The quickly agent at overdose fentanyl who our
The State investigative official lab, received MX highlights year the article has been leads are Minnesota of a introduction tool the noted integral The to prisons. to which that pervasive. for orders A multiple just and samples can in weeks are is to time sent the New the West. applications crucial last the Minnesota for from when process, untenable. England, trace Corrections for We the an take the detection loss of Department which into Midwest narcotics combat Corrections MXXXX fentanyl
progression a we of accounts trials, of result are continuing enterprise such up opportunity In year-end XXXX. we units approximately pilot to XX programs with turn in testing, of representing XXX progression of programs and impact, through from XX valuable pipeline at a the accounts that into pilot build XXXX, opportunity saw As accounts.
diversification accounts provide with in handhelds challenging customers in than In for more our up year-end new with more and opportunity, pleased now the of devices environment. compared XX all XXXX XXXX we’re existing that enterprise we combined Overall, have XXXX. addition, additional product XXX believe across to the amidst macro XX% adoption and bioprocessing our lines
growing accelerating team objective, XX targeted second had our our We to team by commercial to members year-end. commercialization. Turning
the more shifted While close approach this strategic XXXX, investment middle to a the we finished in year macro given the target market. to of we
presence included our This Analytics. through TRACE leveraging our bolstering of acquisition European
as Devices in of entity and to Now we direct and operations GmbH, in customers the and a to base enable European support Germany serve sales XXX have our better region. legal
and Turning us last to providing were acquire our our technology. our core online Analytics We third which developing microfluidics aseptic and product advancing TRACE strengthened portfolio. objective, thrilled technology to sampling biosensor with August,
MAVEN, and free, sampling sterile cell and workflows. with and reduces no lactate costs of lab safe device enables culture the to connects bioreactor, In monitoring processes. This first accelerating loss MAVEN and real-time prep volume cell required. January, operator we time, launched thereby control glucose in that our online and or directly saves providing approach fermentation
as than leverages analytes MAVEN Both acids detect the and are bioprocess including while Mass key leading Mass incorporates technology devices XX the devices for MAVEN REBEL improved simple glucose to Spec. REBEL in are of two to think Spec parameters biosensors difficult discrete control. cell which in REBEL’s as use minutes. to concert. amino and work quantitates detection, less using two lactate XX buddy, our We media nutrients culture additional microscale measure process
great customers well. online the with reduced online we excited and and the to see our our as in are things time think MAVEN this precursor REBEL of lab savings resonate to will It’s market connecting cost We operator a well develop.
we more of the commercial a to million a In seeing MAVEN contribution sampling MAVEN. are gene now products cell and We shipped than as partners. half and QX, fermentation OEM as and for customers related dollars mAb well
creating robust exciting year, also REBEL, and have roadmap we The complementary a here any differentiated. full beyond a analytical product technologies ZipChip, later will this and announce we is and very we’ll key are be that product MAVEN, takeaway of of process another devices, which new portfolio strategy one
results. capability States pesticide wait rather our MXXXX for to the handhelds, in that detect lab illegal USDA with highly Service, to Forest testing to illegal this of weeks the division the device sites We personnel of at and conduct remote safely For marijuana a XXXX we develop United enables its than growth expanded capability pesticides. collaborated field to toxic our
driving now collaborations customers enhance create can developments impactful our awareness and they to of at of state equip expansion work how enterprise our safety. results are data We as to such on devices. this The and the lead better their conversations responders an with as value level to
and module released Aero Our have worked its was customers, with informed we the closely validation. our in customers on our by spring of XXXX
XXXX, We in have seen XXX significant our adoption of this and we accessory customer collaborations. close with shipped credit
the longer runtime time use through funded ease, efforts indoors. same integration with climbed commercial configurations MX work on From for development included Boston rough Spot, stairs yet for enhanced XXXX, outcome. towards with small in alternate communications enough goal is and to projects for In Dynamics’ we traverses terrain RADeCO partnership time, to with selectively drone with customer integration nimble that robot and and
such We will saw QX of license contract and an projects, timing in uptick which the due Joe discuss. revenue to
Our focus year handhelds build team R&D both upon start was a our the in to existing with and the excited hopper commercially a and products we’re our XXXX of product last and for has off capabilities launch new to lot our our desktops.
broadening Turning to bio objective, analytics fourth our platform. our
tech key real-time stack enabler that and inform with analysis predictive a process attribute that support X.X critical Biopharma product to outcomes. quality is better of of goal a models connected Our become devices monitoring
workflows. parameters and REBEL from researchers bioprocessing to at-line Data identify our device process biopharma enables control key in
base enables cell Our ingredient MAVEN monitoring online importantly culture glucose. the control of device and
Our product simple attributes. use ZipChip characterization to offline quality but multiple CMS that device rapid is an of provides
we implementing focused on and needed devices work Over connecting processes biomanufacturing the with institutions leading new XXXX, to and workflows. developing our
in of Our times. for use of feeding and collaboration REBEL and the reduction growth. increase media in a value by nutrients, analysis improved toxic in optimize accumulation cell tighter metabolite has CPI up data design a reduction culture in experiment engineers inform process CPI from to the significant resulting with XX% at-line cell real-time UK-based demonstrated to to strategies
feeding at-line In and where academic novel predictive research AMBIC, and to strategies to researchers T-cell been inform are and develop academic are T-cell models Emory informing working We’ve leveraging power REBEL’s institutions cell consortium, libraries key feeding our media to as improved alliance reliability. using optimize also an quality culture activation. researchers REBEL product such with with microbead for control CAR for developing University, therapies industrial are
publications, a consumption meeting in rapidly AAV process. University is value sensitivity producing such and in cells much user ability with researchers monitor MIT comparable Fudan And in method, high underscored resolution, Bio-Techne, September, REBEL’s and LCMS separations of but at as in volumes. perfusion customers faster conferences to and nutrient ZipChip’s recombinant Connecticut their our and At sample profile of University highlighted high minimal that Boehringer-Ingelheim, to
the support Regeneron an is chromatography alternative a system of Most Journal in variants scientists published types recently, that therapeutic and from method ICEF methods of and Pharmaceuticals ZipChip to more of Analysis, noted paper antibodies. Biomedical CE-MS complimentary our characterization traditional the in Pharmaceutical in to charge different in that
variant for Charge is structure drug the development release. analysis critical understanding biotherapeutics and product during of
the customers We are our a desktop tout process to characterizing delighted as attributes complimentary in and always creating we value of devices our on of and focus hear portfolio products. product complete collaborators
to Foundation, metabolites critical spec when turning Omics mass to based a an fifth workflows, cells as a with working for there’s demand laying our scientists large finally, function, And sample is accelerating proteins orchestrate how objective, and seek rising sets. understand which
As we deliver the to partners, than mass prototype in chips December, and of partnered World a nanoscale for poster chromatography. ion microfluidic sensitivity applications. Scientific with fast chip’s coupling of the XX evaluate increased at Thermo Conference times with demonstrated the shared we’ve trap Washington we with our faster previously, very liquid traditional presented proteomics HUPO Fisher specs In collaboration prototype University to that ability our the
value technologies progress with look progressed in about forward year objectives continued full of excited remain enthusiasm made platform the XXXX Overall, research and scientific at we need. XXXX and these advanced are our and chips about while challenges, confident for the analytics we We QX progress the we microfluidic see this to real-time point presented we year. our the of
financials. on With that, I’ll turn our for detail more to the Joe call over
